March 25, 2021 -- CyanVac has selected contract development and manufacturing organization (CDMO) Exothera for the development and manufacturing of its COVID-19 intranasal vaccine, which is based on a proprietary parainfluenza virus 5 (PIV5) vector.
Exothera will be responsible for the development of a manufacturing process for CyanVac's COVID-19 vaccine candidate, CVXGA1, using the scale-X fixed-bed bioreactor technology platform. The platform, in combination with Exothera's expertise in process development, will enable CyanVac to produce good manufacturing practice (GMP) clinical trial material in 2021 for planned phase III clinical trials.
Clinical trial material will be manufactured at Exothera's Vega GMP plant on the Univercells' Jumet campus in Belgium.
CVXGA1 is a COVID-19 vaccine candidate based on the PIV5 vector that encodes the SARS-CoV-2 spike protein. CyanVac is developing the candidate as a single dose intranasal vaccine to prevent infection and serious complications associated with COVID-19. Preclinical studies suggest that the vaccine is immunogenic and prevents infection. The company is planning a phase I clinical trial in the first half of 2021.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
